交易 Astria Therapeutics, Inc. - ATXS CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
价差 | - | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.024874% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.002651% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平倉 | Change | Change (%) | 開倉 | High | Low |
---|
Astria Therapeutics, Inc. Events
時間(協調世界時) (UTC) | 國家 | 事件 |
---|---|---|
No events scheduled |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
总营业费用 | 53.503 | 194.976 | 37.435 | 27.088 | 26.371 |
销售/一般/行政费用,总计 | 19.239 | 14.807 | 11.845 | 8.771 | 9.329 |
研究与开发 | 34.264 | 180.169 | 25.59 | 18.317 | 17.042 |
营业收入 | -53.503 | -194.976 | -37.435 | -27.088 | -26.371 |
利息收入(费用),非经营净值 | 1.724 | 0.122 | 0.236 | 0.845 | 0.325 |
其他,净值 | -0.055 | -0.058 | -0.101 | -0.05 | 0.176 |
税前净收入 | -51.834 | -194.912 | -37.3 | -26.293 | -25.87 |
税后净收入 | -51.834 | -194.912 | -37.3 | -26.293 | -25.87 |
未计算非常项目前的净收益 | -51.834 | -194.912 | -37.3 | -26.293 | -25.87 |
净收入 | -51.834 | -194.912 | -37.3 | -26.293 | -25.87 |
普通股股东可获收益 (不含非经常性项目) | -51.834 | -219.349 | -37.3 | -26.293 | -25.87 |
普通股股东可获收益 (含非經常性項目) | -51.834 | -219.349 | -37.3 | -26.293 | -25.87 |
摊薄净收入 | -51.834 | -219.349 | -37.3 | -26.293 | -25.87 |
摊薄后加权平均股 | 14.6206 | 8.92517 | 3.05864 | 1.86655 | 0.84249 |
扣除特别项目的每股摊薄盈利 | -3.54527 | -24.5764 | -12.195 | -14.0864 | -30.7067 |
Dividends per Share - Common Stock Primary Issue | |||||
每股正常摊薄盈利 | -3.54527 | -24.5764 | -12.195 | -14.0864 | -30.7067 |
收入 | 0 | ||||
非常规项目总计 | |||||
Total Adjustments to Net Income | 0 | -24.437 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
总营业费用 | 14.29 | 12.386 | 11.449 | 15.378 | 9.508 |
销售/一般/行政费用,总计 | 4.699 | 4.688 | 4.832 | 5.02 | 3.815 |
研究与开发 | 9.591 | 7.698 | 6.617 | 10.358 | 5.693 |
营业收入 | -14.29 | -12.386 | -11.449 | -15.378 | -9.508 |
其他,净值 | 0.009 | -0.048 | -0.015 | -0.001 | -0.016 |
税前净收入 | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
税后净收入 | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
未计算非常项目前的净收益 | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
净收入 | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
普通股股东可获收益 (不含非经常性项目) | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
普通股股东可获收益 (含非經常性項目) | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
摊薄净收入 | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
摊薄后加权平均股 | 18.6982 | 13.7424 | 13.017 | 13.017 | 13.0598 |
扣除特别项目的每股摊薄盈利 | -0.70932 | -0.87299 | -0.86426 | -1.17716 | -0.72673 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
每股正常摊薄盈利 | -0.70932 | -0.87299 | -0.86426 | -1.17716 | -0.72673 |
利息收入(费用),非经营净值 | 1.018 | 0.437 | 0.214 | 0.056 | 0.033 |
Total Adjustments to Net Income | 0 | 0 | 0 | 0 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
流动资产总额 | 127.075 | 46.325 | 38.958 | 38.915 | 17.463 |
现金和短期投资 | 125.508 | 44.93 | 36.244 | 37.57 | 16.369 |
现金等价物 | 1.853 | 22.999 | 5.432 | 5.956 | 16.369 |
短期投资 | 39 | 20 | 26.345 | 22.276 | 0 |
Prepaid Expenses | 1.446 | 1.274 | 2.237 | 1.345 | 1.094 |
Total Assets | 127.514 | 47.456 | 41.78 | 39.169 | 17.897 |
Property/Plant/Equipment, Total - Net | 0.394 | 0.966 | 2.349 | 0.056 | 0.321 |
Property/Plant/Equipment, Total - Gross | 0.377 | ||||
Accumulated Depreciation, Total | -0.321 | ||||
Other Long Term Assets, Total | 0.045 | 0.165 | 0.473 | 0.198 | 0.113 |
Total Current Liabilities | 5.203 | 6.39 | 5.032 | 4.171 | 6.016 |
Accounts Payable | 1.557 | 1.544 | 1.197 | 1.408 | 0.773 |
Accrued Expenses | 3.646 | 4.846 | 3.835 | 2.763 | 2.432 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 2.479 | |||
Total Liabilities | 5.203 | 6.787 | 6.06 | 4.227 | 6.105 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | 0 | ||||
Other Liabilities, Total | 0 | 0.397 | 1.028 | 0.056 | 0.089 |
Total Equity | 122.311 | 40.669 | 35.72 | 34.942 | 11.792 |
Common Stock | 0.013 | 0.02 | 0.012 | 0.007 | 0.024 |
Additional Paid-In Capital | 481.709 | 301.546 | 259.305 | 232.243 | 183.202 |
Retained Earnings (Accumulated Deficit) | -455.809 | -260.897 | -223.597 | -197.304 | -171.434 |
Other Equity, Total | 0 | 0 | -0.004 | 0 | |
Total Liabilities & Shareholders’ Equity | 127.514 | 47.456 | 41.78 | 39.169 | 17.897 |
Total Common Shares Outstanding | 13.017 | 3.34746 | 2.07227 | 0.11903 | 0.3941 |
Other Current Liabilities, Total | 0 | 0.332 | |||
Preferred Stock - Non Redeemable, Net | 96.398 | 0 | 0 | 0 | |
Cash | 84.655 | 1.931 | 4.467 | 9.338 | |
Other Current Assets, Total | 0.121 | 0.121 | 0.477 | ||
Total Preferred Shares Outstanding | 0.03146 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
流动资产总额 | 114.221 | 127.075 | 134.522 | 140.052 | 147.684 |
现金和短期投资 | 112.816 | 125.508 | 131.777 | 139.52 | 146.92 |
现金等价物 | 46.687 | 86.508 | 131.777 | 139.52 | 146.92 |
短期投资 | 66.129 | 39 | 0 | 0 | 0 |
Prepaid Expenses | 1.121 | 1.446 | 2.624 | 0.411 | 0.643 |
Other Current Assets, Total | 0.284 | 0.121 | 0.121 | 0.121 | 0.121 |
Total Assets | 114.653 | 127.514 | 135.129 | 140.945 | 148.74 |
Property/Plant/Equipment, Total - Net | 0.228 | 0.394 | 0.557 | 0.717 | 0.874 |
Other Long Term Assets, Total | 0.204 | 0.045 | 0.05 | 0.176 | 0.182 |
Total Current Liabilities | 4.967 | 5.203 | 4.7 | 3.988 | 4.406 |
Accounts Payable | 0.931 | 1.557 | 0.574 | 0.619 | 1.809 |
Accrued Expenses | 4.036 | 3.646 | 4.126 | 3.369 | 2.597 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4.967 | 5.203 | 4.7 | 4.046 | 9.004 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0 | 0 | 0.058 | 4.598 | |
Total Equity | 109.686 | 122.311 | 130.429 | 136.899 | 139.736 |
Preferred Stock - Non Redeemable, Net | 96.398 | 96.398 | 96.398 | 99.77 | 240.881 |
Common Stock | 0.013 | 0.013 | 0.013 | 0.077 | 0.023 |
Additional Paid-In Capital | 484.46 | 481.709 | 480.336 | 475.499 | 329.813 |
Retained Earnings (Accumulated Deficit) | -471.132 | -455.809 | -446.318 | -438.447 | -430.981 |
Total Liabilities & Shareholders’ Equity | 114.653 | 127.514 | 135.129 | 140.945 | 148.74 |
Total Common Shares Outstanding | 13.017 | 13.017 | 13.0095 | 12.8248 | 3.90283 |
Total Preferred Shares Outstanding | 0.03146 | 0.03146 | 0.03146 | 0.03255 | |
Other Equity, Total | -0.053 | 0 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -51.834 | -194.912 | -37.3 | -26.293 | -25.87 |
经营活动产生的现金 | -43.533 | -30.151 | -32.485 | -26.569 | -23.465 |
经营活动产生的现金 | 0.026 | 0.119 | |||
非现金物品 | 5.654 | 168.066 | 1.448 | 1.568 | 1.524 |
已付现金利息 | 0 | 0.079 | |||
营运资金的变化 | 2.647 | -3.305 | 3.367 | -1.87 | 0.762 |
投资活动产生的现金 | -167.129 | -12.555 | 6.3 | -4.082 | -21.905 |
资本支出 | -0.091 | -0.021 | -0.033 | -0.012 | 0 |
其他投资现金流量项目,总计 | -167.038 | -12.534 | 6.333 | -4.07 | -21.905 |
融资活动产生的现金 | 144.721 | 104.284 | 40.86 | 25.62 | 44.295 |
股票的发行(报废),净额 | 144.721 | 104.284 | 40.86 | 25.62 | 47.143 |
债务的发行(退还),净额 | 0 | -2.848 | |||
现金净变化 | -65.941 | 61.578 | 14.675 | -5.031 | -1.075 |
融资现金流项目 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -51.834 | -38.571 | -26.574 | -15.323 | -194.912 |
Cash From Operating Activities | -43.533 | -32.869 | -22.62 | -12.559 | -30.151 |
Non-Cash Items | 5.654 | 5.15 | 3.947 | 2.672 | 168.066 |
Changes in Working Capital | 2.647 | 0.552 | 0.007 | 0.092 | -3.305 |
Cash From Investing Activities | -167.129 | -31.949 | -33.899 | -27.099 | -12.555 |
Capital Expenditures | -0.091 | -0.06 | -0.002 | 0 | -0.021 |
Other Investing Cash Flow Items, Total | -167.038 | -31.889 | -33.897 | -27.099 | -12.534 |
Cash From Financing Activities | 144.721 | 24.324 | 0 | 0 | 104.284 |
Issuance (Retirement) of Stock, Net | 144.721 | 24.324 | 0 | 0 | 104.284 |
Net Change in Cash | -65.941 | -40.494 | -56.519 | -39.658 | 61.578 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
Fidelity Management & Research Company LLC | Investment Advisor | 11.9754 | 3351514 | 2974069 | 2022-12-31 | LOW |
Perceptive Advisors LLC | Private Equity | 7.8232 | 2189462 | 908265 | 2022-12-31 | MED |
Fairmount Funds Management LLC | Hedge Fund | 6.7939 | 1901397 | 989661 | 2022-12-31 | HIGH |
Deep Track Capital LP | Hedge Fund | 6.4907 | 1816531 | 1816531 | 2022-12-31 | MED |
Vivo Capital, LLC | Venture Capital | 6.0071 | 1681199 | 681199 | 2022-12-31 | MED |
Cormorant Asset Management, LP | Hedge Fund | 5.8957 | 1650000 | 450000 | 2022-12-31 | MED |
Altium Capital Management LP | Investment Advisor/Hedge Fund | 4.8429 | 1355372 | 910372 | 2022-12-31 | HIGH |
Driehaus Capital Management, LLC | Investment Advisor/Hedge Fund | 4.7784 | 1337315 | 680954 | 2022-12-31 | MED |
Logos Global Management LLC | Investment Advisor | 3.0906 | 864960 | 864960 | 2022-12-31 | HIGH |
Ikarian Capital LLC | Hedge Fund | 2.4125 | 675176 | -24264 | 2022-12-31 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.338 | 654326 | 123173 | 2022-12-31 | LOW |
Rosalind Advisors, Inc. | Hedge Fund | 2.3348 | 653438 | 653438 | 2021-12-31 | LOW |
Tri Locum Partners LP | Hedge Fund | 2.3273 | 651330 | 19751 | 2022-12-31 | HIGH |
Affinity Asset Advisors LLC | Hedge Fund | 1.6882 | 472482 | 72439 | 2022-12-31 | HIGH |
Sphera Funds Management Ltd. | Hedge Fund | 1.677 | 469340 | 469340 | 2022-12-31 | MED |
Ghost Tree Capital, LLC | Hedge Fund | 1.6079 | 450000 | -50000 | 2022-12-31 | HIGH |
Violin (Jonathan) | Individual Investor | 0.9409 | 263321 | 0 | 2022-04-13 | LOW |
Opaleye Management Inc. | Hedge Fund | 0.9351 | 261703 | 128203 | 2022-12-31 | MED |
Medical Strategy GmbH | Investment Advisor | 0.9026 | 252605 | -18814 | 2022-09-30 | LOW |
Point72 Asset Management, L.P. | Hedge Fund | 0.804 | 225000 | 225000 | 2022-12-31 | HIGH |
交易計算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
貿易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
開倉
平倉
做空 做多
Astria Therapeutics, Inc. Company profile
关于 Astria Therapeutics Inc.
Astria Therapeutics公司,前身为Catabasis Pharmaceuticals公司,是一家生物制药公司。 该公司专注于为受罕见和利基过敏性和免疫性疾病影响的患者和家庭开发治疗方法。 其主导项目STAR-0215正处于临床前开发阶段,用于治疗遗传性血管性水肿(HAE)。 HAE是一种罕见的遗传性疾病,其特点是严重的、反复的、不可预测的、痛苦的、有时危及生命的面部、四肢、腹部和气道肿胀。 STAR-0215是一种血浆卡利克蛋白的单克隆抗体抑制剂,旨在为HAE提供长效的攻击预防。
Industry: | Bio Therapeutic Drugs |
75 State Street
Suite 1400
BOSTON
MASSACHUSETTS 02109
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球500,000万多名交易者的一份子,选择利用Capital.com进行交易吧。